Outcomes After Chemotherapy Followed by Radiation for Stage IIB Hodgkin Lymphoma With Bulky Disease.

[1]  Christine F. Wogan,et al.  Improvements in Treatments for Hodgkin Lymphoma Over a 50-Year Period Lead to Fewer Second Malignancies , 2014 .

[2]  A. Ng,et al.  Long-Term Competing Mortality in Early-Stage Hodgkin Lymphoma: Reduced Mortality Risk in Patients Treated in the Modern Era , 2014 .

[3]  R. Advani,et al.  Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. , 2012, Journal of the National Comprehensive Cancer Network : JNCCN.

[4]  C. Wendtner,et al.  Multimodale Therapiekonzepte bei Weichteilsarkomen , 2010, Der Internist.

[5]  R. Greil,et al.  Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Greil,et al.  Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. , 2010, The New England journal of medicine.

[7]  D. Brenner,et al.  Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma , 2007, Cancer.

[8]  Sigrid Stroobants,et al.  Revised response criteria for malignant lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  J. Raemaekers,et al.  Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  E. Noordijk,et al.  Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  R. Clough,et al.  Combined-modality therapy versus radiotherapy alone for treatment of early-stage Hodgkin's disease: cure balanced against complications. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  G. Bonadonna,et al.  ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  Dirk Hasenclever,et al.  Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  H. Bartelink,et al.  Long-term cause-specific mortality of patients treated for Hodgkin's disease. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  K. Propert,et al.  Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. , 1992, The New England journal of medicine.

[16]  H. Eich,et al.  [Multimodality therapy concepts for soft tissue sarcomas]. , 2010, Der Internist.

[17]  B. Meunier,et al.  [Breast cancer after treatment of Hodgkin's disease]. , 1995, Journal de gynecologie, obstetrique et biologie de la reproduction.